Antimicrobial defense systems in saliva

Monographs in Oral Science

Volumn 24, Issue , 2014, Pages 40-51

  Van'T Hof, Wim ^a   Veerman, Enno C I ^a   Amerongen, Arie V Nieuw ^a   Ligtenberg, Antoon J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; SALIVA PROTEIN;

ARTICLE; BACTERIUM; BACTERIUM ADHERENCE; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL CONSORTIUM; MICROBIOLOGY; MOUTH; PHYSIOLOGY; SALIVA;

ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL ADHESION; HUMANS; MICROBIAL CONSORTIA; MOUTH; SALIVA; SALIVARY PROTEINS AND PEPTIDES;

EID: 84904651950     PISSN: 00770892     EISSN: 16623843     Source Type: Book Series    
DOI: 10.1159/000358783     Document Type: Article

References (129)

1. Vissink A, Panders AK, 's-Gravenmade EJ, Vermey A: The causes and consequences of hyposalivation. Ear Nose Throat J 1988; 67: 166.
2. Dennesen P, van der Ven A, Vlasveld M, Lokker L, Ramsay G, Kessels A, van den Keijbus P, Nieuw Amerongen AV, Veerman ECI: Inadequate salivary flow and poor oral mucosal status in intubated intensive care unit patients. Crit Care Med 2003; 31: 781-786.
3. Siqueira WL, Custodio W, McDonald EE: New insights into the composition and functions of the acquired enamel pellicle. J Dent Res 2012; 91: 1110-1118.
4. Schlesinger DH, Hay DI: Complete covalent structure of statherin, a tyrosinerich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva. J Biol Chem 1977; 252: 1689-1695.
5. Amano A, Kataoka K, Raj PA, Genco RJ, Shizukuishi S: Binding sites of salivary statherin for Porphyromonas gingivalis recombinant fimbrillin. Infect Immun 1996; 64: 4249-4254.
6. Rudney JD, Staikov RK, Johnson JD: Potential biomarkers of human salivary function: a modified proteomic approach. Arch Oral Biol 2009; 54: 91-100.
7. Cannon RD, Nand AK, Jenkinson HF: Adherence of Candida albicans to human salivary components adsorbed to hydroxylapatite. Microbiology 1995; 141: 213-219.
8. Johansson I, Bratt P, Hay DI, Schluckebier S, Strømberg N: Adhesion of Candida albicans, but not Candida krusei, to salivary statherin and mimicking host molecules. Oral Microbiol Immunol 2000; 15: 112-118.
9. Gibbons RJ, Hay DI, Cisar JO, Clark WB: Adsorbed salivary proline-rich protein-1 and statherin - receptors for type-1 fimbriae of Actinomyces viscosus T14V-J1 on apatitic surfaces. Infect Immun 1988; 56: 2990-2993.
10. Kataoka K, Amano A, Kuboniwa M, Horie H, Nagata H, Shizukuishi S: Active sites of salivary proline-rich protein for binding to Porphyromonas gingivalis fimbriae. Infect Immun 1997;65:3159-3164.
11. Karlsson NG, Schulz BL, Packer NH: Structural determination of neutral Olinked oligosaccharide alditols by negative ion LC-electronspray-MSn. J Am Soc Mass Spectrom 2004; 15: 659-672.
12. Veerman ECI, Ligtenberg AJM, Schenkels LPCM, Walgreen-Weterings E, Nieuw Amerongen AV: Binding of human high-molecular weight salivary mucins (MG1) to Haemophilus parainfluenzae. J Dent Res 1995;74 : 351-357.
13. Veerman ECI, Bank CMC, Namavar F, Appelmelk BJ, Bolscher JGM, Nieuw Amerongen AV: Sulfated glycans on oral mucin as receptors for Helicobacter pylori. Glycobiology 1997; 7: 737-743.
14. Bosch JA, de Geus EJ, Ligtenberg TJ, Nazmi K, Veerman EC, Hoogstraten J, Nieuw Amerongen AV: Salivary MUC5B-mediated adherence (ex vivo) of Helicobacter pylori during acute stress. Psychosom Med 2000; 62: 40-49.
15. Dawes C: How much saliva is enough for avoidance of xerostomia? Caries Res 2004; 38: 236-240.
16. Levine MJ, Reddy MS, Tabak LA, Loomis RE, Bergey EJ, Jones PC, Cohen RE, Stinson MW, Al-Hashimi I: Structural aspects of salivary glycoproteins. J Dent Res 1987; 66: 436-441.
17. Tabak LA: Structure and function of human salivary mucins. Crit Rev Oral Biol Med 1990; 1: 229-234.
18. Bolscher JG, Groenink J, van der Kwaak JS, van den Keijbus PA, van 't Hof W, Veerman EC, Nieuw Amerongen AV: Detection and quantification of MUC7 in submandibular, sublingual, palatine, and labial saliva by anti-peptide antiserum. J Dent Res 1999; 78: 1362-1369.
19. Murray PA, Prakobphol A, Lee T, Hoover CI, Fisher SJ: Adherence of oral streptococci to salivary glycoproteins. Infect Immun 1992; 60: 31-38.
20. Reddy MS, Levine MJ, Paranchych W: Low-molecular-mass human salivary mucin, MG2: structure and binding of Pseudomonas aeruginosa. Crit Rev Oral Biol Med 1993; 4: 315-323.
21. Groenink J, Ligtenberg AJM, Veerman ECI, Bolscher JGM, Nieuw Amerongen AV: Interaction of the salivary low-molecular- weight mucin (MG2) with Actinobacillus actinomycetemcomitans. Antonie van Leeuwenhoek 1996; 70: 79-87.
22. Moshier A, Reddy MS, Scannapieco FA: Role of type fimbriae in the adhesion of Escherichia coli to salivary mucin and secretory immunoglobulin A. Curr Microbiol 1996; 33: 200-208.
23. Liu B, Rayment S, Oppenheim FG, Troxler RF: Isolation of human salivary mucin MG2 by a novel method and characterization of its interactions with oral bacteria. Arch Biochem Biophys 1999; 364: 286-293.
24. Liu B, Rayment SA, Gyurko C, Oppenheim FG, Offner GD, Troxler RF: The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral streptococci and exhibits candidacidal activity. Biochem J 2000; 345: 557-564.
25. Biesbrock AR, Reddy MS, Levine MJ: Interaction of a salivary mucin-secretory immunoglobulin A complex with mucosal pathogens. Infect Immun 1991; 59: 3492-3497.
26. Holmskov U, Mollenhauer J, Madsen J, Vitved L, Grønlund J, Tornoe I, Kliem A, Reid KBM, Poustka A, Skjødt K: Cloning of GP-340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci USA 1999; 96: 10794-10799.
27. Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrøm J, Johansson I, Frangsmyr L, Holmskov U, Leffler H, Nilsson C, Boren T, Wright JR, Strømberg N, Fisher SJ: Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340. J Biol Chem 2000; 275: 39860-39866.
28. Ligtenberg TJM, Bikker FJ, Groenink J, Tornoe I, Leth-Larsen R, Veerman ECI, Nieuw Amerongen AV, Holmskov U: Human salivary agglutinin binds to lung surfactant protein-D and is identical with scavenger receptor protein gp-340. Biochem J 2001; 359: 243-248.
29. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV, Mollenhauer J: Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer. Biol Chem 2007; 388: 1275-1289.
30. Martinez VG, Moestrup SK, Holmskov U, Mollenhauer J, Lozano F: The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. Pharmacol Rev 2011; 63: 967-1000.
31. Sarrias MR, Grønlund J, Padilla O, Madsen J, Holmskov U, Lozano F: The scavenger receptor cysteine-rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 2004; 24: 1-37.
32. Ericson T, Rundegren J: Characterization of a salivary agglutinin reacting with a serotype c strain of Streptococcus mutans . Eur J Biochem 1983; 133: 255-261.
33. Leito JT, Ligtenberg AJ, van Houdt M, van den Berg TK, Wouters D: The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates complement via the lectin pathway. Mol Immunol 2011; 49: 185-190.
34. Corthesy B: Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. Future Microbiol 2010; 5: 817-829.
35. Brandtzaeg P: Secretory immunity with special reference to the oral cavity. J Oral Microbiol 2013, Epub ahead of print.
36. Upton M, Tagg JR, Wescombe P, Jenkinson HF: Intra- and interspecies signaling between Streptococcus salivarius and Streptococcus pyogenes mediated by SalA and SalA1 lantibiotic peptides. J Bacteriol 2001; 183: 3931-3938.
37. Kolenbrander PE: Multispecies communities: interspecies interactions influence growth on saliva as sole nutritional source. Int J Oral Sci 2011; 3: 49-54.
38. Van der Hoeven JS, van den Kieboom CWA, Camp PJM: Utilization of mucin by oral Streptococcus species. Antonie van Leeuwenhoek 1990; 57: 165-172.
39. Ibrahim HR, Matsuzaki T, Aoki T: Genetic evidence that antibacterial activity of lysozyme is independent of its catalytic function. FEBS Lett 2001; 506: 27-32.
40. Ihalin R, Loimaranta V, Tenovuo J: Origin, structure, and biological activities of peroxidases in human saliva. Arch Biochem Biophys 2006; 445: 261-268.
41. Ashby MT: Inorganic chemistry of defensive peroxidases in the human oral cavity. J Dent Res 2008; 87: 900-914.
42. Alves MB, Motta AC, Messina WC, Migliari DA: Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. Quintessence Int 2004; 35: 392-396.
43. Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-555.
44. Groenink J, Walgreen-Weterings J, Nazmi K, Bolscher JGM, Winkelhoff AJ, Nieuw Amerongen AV: Salivary lactoferrin and low M r mucin MG2 in Actinobacillus actinomycetemcomitans -associated periodontitis. J Clin Periodontol 2000; 26: 269-275.
45. Groenink J, Walgreen-Weterings E, van 't Hof W, Veerman ECI, Nieuw Amerongen AV: Cationic amphipatic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiol Lett 1999; 179: 217-222.
46. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M: Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130-136.
47. Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP: Lactoferrin: antimicrobial activity and therapeutic potential. Semin Fetal Neonatal Med 2013, Epub ahead of print.
48. Leito JT, Ligtenberg AJ, Nazmi K, Veerman EC: Identification of salivary components that induce transition of hyphae to yeast in Candida albicans. FEMS Yeast Res 2009; 9: 1102-1110.
49. Bencharit S, Altarawneh SK, Baxter SS, Carlson J, Ross GF, Border MB, Mack CR, Byrd WC, Dibble CF, Barros S, Loewy Z, Offenbacher S: Elucidating role of salivary proteins in denture stomatitis using a proteomic approach. Mol Biosyst 2012; 8: 3216-3223.
50. Isola M, Lantini M, Solinas P, Diana M, Isola R, Loy F, Cossu M: Diabetes affects statherin expression in human labial glands. Oral Dis 2011; 17: 685-689.
51. Isola M, Solinas P, Proto E, Cossu M, Lantini MS: Reduced statherin reactivity of human submandibular gland in diabetes. Oral Dis 2011; 17: 217-220.
52. Isola M, Cossu M, Diana M, Isola R, Loy F, Solinas P, Lantini MS: Diabetes reduces statherin in human parotid: immunogold study and comparison with submandibular gland. Oral Dis 2012; 18: 360-364.
53. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
54. Mochon AB, Liu H: The antimicrobial peptide histatin-5 causes a spatially restricted disruption on the Candida albicans surface, allowing rapid entry of the peptide into the cytoplasm. PLoS Pathog 2008; 4:e1000190.
55. Helmerhorst EJ, van 't Hof W, Veerman EC, Simoons-Smit I, Nieuw Amerongen AV: Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem J 1997; 326: 39-45.
56. Pollock JJ, Denepitiya L, MacKay BJ, Iacono VJ: Fungistatic and fungicidal activity of human parotid salivary histidine- rich polypeptides on Candida albicans. Infect Immun 1984; 44: 702-707.
57. MacKay BJ, Denepitiya L, Iacono VJ, Krost SB, Pollock JJ: Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect Immun 1984; 44: 695-701.
58. Sabatini LM, He YZ, Azen EA: Structure and sequence determination of the gene encoding human salivary statherin. Gene 1990; 89: 245-251.
59. Van der Spek JC, Offner GD, Troxler RF, Oppenheim FG: Molecular cloning of human submandibular histatins. Arch Oral Biol 1990; 35: 137-143.
60. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner GD, Troxler RF: Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988; 263: 7472-7477.
61. Oppenheim FG, Yang YC, Diamond RD, Hyslop D, Offner GD, Troxler RF: The primary structure and functional characterization of the neutral histidine-rich polypeptide from human parotid secretion. J Biol Chem 1986; 261: 1177-1182.
62. Sun X, Salih E, Oppenheim FG, Helmerhorst EJ: Kinetics of histatin proteolysis in whole saliva and the effect on bioactive domains with metal-binding, antifungal, and wound-healing properties. FASEB J 2009; 23: 2691-2701.
63. Helmerhorst EJ, Breeuwer P, van 't Hof W, Walgreen-Weterings E, Oomen LCJM, Veerman ECI, Nieuw Amerongen AV, Abee T: The cellular target of histatin5 on Candida albicans is the energized mitochondrion. J Biol Chem 1999; 274: 7286-7291.
64. Edgerton M, Koshlukova SE, Lo TE, Chrzan BG, Straubinger RM, Raj PA: Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J Biol Chem 1998; 273: 20438-20447.
65. Ruissen ALA, Groenink J, Helmerhorst EJ, Walgreen-Weterings E, van 't Hof W, Veerman EC, Nieuw Amerongen AV: Effects of histatin5 and derived peptides on Candida albicans. Biochem J 2001; 356: 361-368.
66. Li XS, Sun JN, Okamoto-Shibayama K, Edgerton M: Candida albicans cell wall ssa proteins bind and facilitate import of salivary histatin5 required for toxicity. J Biol Chem 2006; 281: 22453-22463.
67. Li XS, Reddy MS, Baev D, Edgerton M: Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J Biol Chem 2003; 278: 28553-28561.
68. Luque-Ortega JR, van 't Hof W, Veerman EC, Saugar JM, Rivas L: Human antimicrobial peptide histatin5 is a cellpenetrating peptide targeting mitochondrial ATP synthesis in Leishmania . FASEB J 2008; 22: 1817-1828.
69. Harder J, Bartels J, Christophers E, Schröder JM: Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
70. Harder J, Siebert R, Zhang Y, Matthiesen P, Christophers E, Schlegelberger B, Schröder JM: Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics 1997; 46: 472-475.
71. Schröder JM, Harder J: Human beta-defensin- 2. Int J Biochem Cell Biol 1999; 31: 645-651.
72. Abiko Y, Saitoh M: Salivary defensins and their importance in oral health and disease. Curr Pharm Des 2007; 13: 3065-3072.
73. Dunsche A, Acil Y, Siebert R, Harder J, Schröder JM, Jepsen S: Expression profile of human defensins and antimicrobial proteins in oral tissues. J Oral Pathol Med 2001; 30: 154-158.
74. Gursoy UK, Kononen E, Luukkonen N, Uitto VJ: Human neutrophil defensins and their effect on epithelial cells. J Periodontol 2013; 84: 126-133.
75. Gursoy UK, Kononen E: Understanding the roles of gingival beta-defensins. J Oral Microbiol 2012, Epub ahead of print.
76. Mathews M, Jia HP, Guthmiller J, Losh G, Graham S, Johnson GK, Tack BF, Mc- Cray PB: Production of beta defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; 67: 2740-2745.
77. Weinberg A, Krisanaprakornkit S, Dale BA: Epithelial antimicrobial peptides: review and significance for oral applications. Crit Rev Oral Biol Med 1998; 9: 399-414.
78. Maisetta G, Batoni G, Esin S, Raco G, Bottai D, Favilli F, Florio W, Campa M: Susceptibility of Streptococcus mutans and Actinobacillus actinomycetemcomitans to bactericidal activity of human beta-defensin3 in biological fluids. Antimicrob Agents Chemother 2005; 49: 1245-1248.
79. Mineshiba F, Takashiba S, Mineshiba J, Matsuura K, Kokeguchi S, Murayama Y: Antibacterial activity of synthetic human B defensin-2 against periodontal bacteria. J Int Acad Periodontol 2003; 5: 35-40.
80. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, Sayama K, Hashimoto K, Kurihara H, Sugai M: Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {beta}-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-896.
81. Weinberg A, Quinones-Mateu ME, Lederman MM: Role of human beta-defensins in HIV infection. Adv Dent Res 2006; 19: 42-48.
82. Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, Wilson JM: Human beta-defensin2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102: 874-880.
83. Maisetta G, Batoni G, Esin S, Luperini F, Pardini M, Bottai D, Florio W, Giuca MR, Gabriele M, Campa M: Activity of human beta-defensin3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother 2003; 47: 3349-3351.
84. Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA: Inducible expression of human beta-defensin2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun 2000; 68: 2907-2915.
85. Shin J, Choi Y: The fate of Treponema denticola within human gingival epithelial cells. Mol Oral Microbiol 2012; 27: 471-482.
86. Shin JE, Choi Y: Treponema denticola suppresses expression of human betadefensin-2 in gingival epithelial cells through inhibition of TNFalpha production and TLR2 activation. Mol Cells 2010; 29: 407-412.
87. Pereira AL, Franco GC, Cortelli SC, Aquino DR, Costa FO, Raslan SA, Cortelli JR: Influence of periodontal status and periodontopathogens on levels of oral human beta-defensin-2 in saliva. J Periodontol 2013; 84: 1445-1453.
88. Sawaki K, Mizukawa N, Yamaai T, Fukunaga J, Sugahara T: Immunohistochemical study on expression of alphadefensin and beta-defensin-2 in human buccal epithelia with candidiasis. Oral Dis 2002; 8: 37-41.
89. Conti HR, Baker O, Freeman AF, Jang WS, Holland SM, Li RA, Edgerton M, Gaffen SL: New mechanism of oral immunity to mucosal candidiasis in hyper- IgE syndrome. Mucosal Immunol 2011; 4: 448-455.
90. Yang D, Biragyn A, Kwak LW, Oppenheim JJ: Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002; 23: 291-296.
91. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schröder JM, Wang JM, Howard OM, Oppenheim JJ: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-528.
92. Niyonsaba F, Ogawa H, Nagaoka I: Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor- alpha-treated human neutrophils. Immunology 2004; 111: 273-281.
93. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I: Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002; 14: 421-426.
94. Niyonsaba F, Ushio H, Hara M, Yokoi H, Tominaga M, Takamori K, Kajiwara N, Saito H, Nagaoka I, Ogawa H, Okumura K: Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 2010; 184: 3526-3534.
95. Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, Nagaoka I, Okumura K, Ogawa H: Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007; 127: 594-604.
96. Diamond G, Ryan L: Beta-defensins: what are they really doing in the oral cavity? Oral Dis 2011; 17: 628-635.
97. Den Hertog AL, van Marle J, van Veen HA, van 't Hof W, Bolscher JG, Veerman EC, Nieuw Amerongen AV: Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J 2005; 388: 689-695.
98. Den Hertog AL, van Marle J, Veerman EC, Valentijn-Benz M, Nazmi K, Kalay H, Grun CH, van 't Hof W, Bolscher JG, Nieuw Amerongen AV: The human cathelicidin peptide LL-37 and truncated variants induce segregation of lipids and proteins in the plasma membrane of Candida albicans. Biol Chem 2006; 387: 1495-1502.
99. Barlow PG, Beaumont PE, Cosseau C, Mackellar A, Wilkinson TS, Hancock RE, Haslett C, Govan JR, Simpson AJ, Davidson DJ: The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. Am J Respir Cell Mol Biol 2010; 43: 692-702.
100. Bowdish DM, Davidson DJ, Scott MG, Hancock RE: Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 2005; 49: 1727-1732.
101. Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G: Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 2011; 32: 1807-1814.
102. Van Boven JF, de Jong-van den Berg LT, Vegter S: Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf 2013; 36: 231-236.
103. Reichhardt MP, Loimaranta V, Thiel S, Finne J, Meri S, Jarva H: The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces. Front Immunol 2012; 3: 205.
104. Nieuw Amerongen AV, Veerman EC: Saliva - the defender of the oral cavity. Oral Dis 2002; 8: 12-22.
105. Fernandes FR, Nagao AT, Mayer MP, Zelante F, Carneiro-Sampaio MM: Compensatory levels of salivary IgM anti- Streptococcus mutans antibodies in IgA-deficient patients. J Investig Allergol Clin Immunol 1995; 5: 151-155.
106. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MA, Geuking MB, Beutler B, Tedder TF, Hardt WD, Bercik P, Verdu EF, McCoy KD, Macpherson AJ: Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009; 325: 617-620.
107. Bolscher JG, Nazmi K, Ran LJ, van Engelenburg FA, Schuitemaker H, Veerman EC, Nieuw Amerongen AV: Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. Eur J Oral Sci 2002; 110: 149-156.
108. Baik JE, Hong SW, Choi S, Jeon JH, Park OJ, Cho K, Seo DG, Kum KY, Yun CH, Han SH: Alpha-amylase is a human salivary protein with affinity to lipopolysaccharide of Aggregatibacter actinomycetemcomitans. Mol Oral Microbiol 2013; 28: 142-153.
109. Choi S, Baik JE, Jeon JH, Cho K, Seo DG, Kum KY, Yun CH, Han SH: Identification of Porphyromonas gingivalis lipopolysaccharide-binding proteins in human saliva. Mol Immunol 2011; 48: 2207-2213.
110. Blankenvoorde MFJ, van 't Hof W, Walgreen-Weterings E, van Steenbergen TJMBH, Veerman ECI, Nieuw Amerongen AV: Cystatin and cystatinderived peptides have antibacterial activity against the pathogen Porphyromonas gingivalis. Biol Chem 1998; 379: 1371-1375.
111. Redl B: Human tear lipocalin. Biochim Biophys Acta 2000; 1482: 241-248.
112. Lechner M, Wojnar P, Redl B: Human tear lipocalin acts as an oxidativestress- induced scavenger of potentially harmful lipid peroxidation products in a cell culture system. Biochem J 2001; 356: 129-135.
113. Yusifov TN, Abduragimov AR, Gasymov OK, Glasgow BJ: Endonuclease activity in lipocalins. Biochem J 2000; 347: 815-819.
114. Schenkels LC, Walgreen-Weterings E, Oomen LC, Bolscher JG, Veerman EC, Nieuw Amerongen AV: In vivo binding of the salivary glycoprotein EP-GP (identical to GCDFP-15) to oral and non-oral bacteria detection and identification of EP-GP binding species. Biol Chem 1997; 378: 83-88.
115. Autiero M, Gaubin M, Mani JC, Castejon C, Martin MES, Guardiola J, Piatiertonneau D: Surface plasmon resonance analysis of gp17, a natural CD4 ligand from human seminal plasma inhibiting human immunodeficiency virus type-1 gp120-mediated syncytium formation. Eur J Biochem 1997; 245: 208-213.
116. Gaubin M, Auteiro M, Basmaciogullari S, Metivier D, Misehal Z, Culerrier R, Oudin A, Guardiola J, Piatier-Tonneau D: Potent inhibition of CD4/TCR-mediated T cell apoptosis by a CD-4 binding glycoprotein secreted from breast tumor and seminal vessicle. J Immunol 1999; 162: 2631-2638.
117. Van Steijn GJ, Nieuw Amerongen AV, Veerman EC, Kasanmoentalib S, Overdijk B: Chitinase in whole and glandular human salivas and in whole saliva of patients with periodontal inflammation. Eur J Oral Sci 1999; 107: 328-337.
118. Robinovitch MR, Ashley RL, Iversen JM, Vigoren EM, Oppenheim FG, Lamkin M: Parotid salivary basic proline- rich proteins inhibit HIV-I infectivity. Oral Dis 2001; 7: 86-93.
119. Walz A, Odenbreit S, Stuhler K, Wattenberg A, Meyer HE, Mahdavi J, Boren T, Ruhl S: Identification of glycoprotein receptors within the human salivary proteome for the lectin-like BabA and SabA adhesins of Helicobacter pylori by fluorescence-based 2-D bacterial overlay. Proteomics 2009; 9: 1582-1592.
120. Walz A, Odenbreit S, Mahdavi J, Boren T, Ruhl S: Identification and characterization of binding properties of Helicobacter pylori by glycoconjugate arrays. Glycobiology 2005; 15: 700-708.
121. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC: Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun 2004; 72: 1956-1963.
122. Dziarski R, Kashyap DR, Gupta D: Mammalian peptidoglycan recognition proteins kill bacteria by activating twocomponent systems and modulate microbiome and inflammation. Microb Drug Resist 2012; 18: 280-285.
123. Dziarski R, Gupta D: Review: mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity. Innate Immun 2010; 16: 168-174.
124. Fonseca-Maldonado R, Ferreira TL, Ward RJ: The bacterial effect of human secreted group IID phospholipase A2 results from both hydrolytic and nonhydrolytic activities. Biochimie 2012;94:1437-1440.
125. Brauer L, Moschter S, Beileke S, Jager K, Garreis F, Paulsen FP: Human parotid and submandibular glands express and secrete surfactant proteins A, B, C and D. Histochem Cell Biol 2009; 132: 331-338.
126. Chen CH, Zhang XQ, Lo CW, Liu PF, Liu YT, Gallo RL, Hsieh MF, Schooley RT, Huang CM: The essentiality of alpha-2-macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus. Proteomics 2010; 10: 2396-2401.
127. Sweet SP, Denbury AN, Challacombe SJ: Salivary calprotectin levels are raised in patients with oral candidiasis or Sjögren's syndrome but decreased by HIV infection. Oral Microbiol Immunol 2001; 16: 119-123.
128. Sugawara S, Uehara A, Tamai R, Takada H: Innate immune responses in oral mucosa. J Endotoxin Res 2002; 8: 465-468.
129. Uehara A, Sugawara S, Watanabe K, Echigo S, Sato M, Yamaguchi T, Takada H: Constitutive expression of a bacterial pattern recognition receptor, CD14, in human salivary glands and secretion as a soluble form in saliva. Clin Diagn Lab Immunol 2003; 10: 286-292